The neuroprotective properties of GLP-1 have become an exciting area of research, particularly for neurodegenerative diseases. GLP-1 and its analogs reduce inflammation in brain cells, potentially slowing disease progression in Alzheimer’s and Parkinson’s. Studies show that GLP-1 decreases microglial activation, which is linked to neuroinflammation, and may also reduce amyloid plaque buildup in Alzheimer's. Animal models indicate that GLP-1 therapies support memory, cognitive function, and overall brain health. These findings suggest GLP-1’s potential as a neuroprotective agent, adding another layer to its therapeutic applications in both metabolic and neurological diseases.
Mehdi, S.F., Pusapati, S., Anwar, M.S., Lohana, D., Kumar, P., Nandula, S.A., Nawaz, F.K., Tracey, K., Yang, H., LeRoith, D., Brownstein, M.J. and Roth, J., 2023. Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent. Frontiers in Immunology
Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.
For detailed information about SEMAGLUTIDE by Rohm Labs, consult with your doctor or healthcare professional.
Mehdi, S.F., Pusapati, S., Anwar, M.S., Lohana, D., Kumar, P., Nandula, S.A., Nawaz, F.K., Tracey, K., Yang, H., LeRoith, D., Brownstein, M.J. and Roth, J., 2023. Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent. Frontiers in Immunology
Mehdi, S.F., Pusapati, S., Anwar, M.S., Lohana, D., Kumar, P., Nandula, S.A., Nawaz, F.K., Tracey, K., Yang, H., LeRoith, D., Brownstein, M.J. and Roth, J., 2023. Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent. Frontiers in Immunology
Mehdi, S.F., Pusapati, S., Anwar, M.S., Lohana, D., Kumar, P., Nandula, S.A., Nawaz, F.K., Tracey, K., Yang, H., LeRoith, D., Brownstein, M.J. and Roth, J., 2023. Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent. Frontiers in Immunology
Home
